Interview: Diane Gosselin, President and CEO, CQDM, Canada
The president & CEO of CQDM discusses her vision of how CQDM’s activities can have a direct impact on the development of safer and more efficient drugs, and how to…
CQDM is a not-for-profit organization whose mission is to identify, fund and support joint research projects between the academic and private biopharmaceutical sectors. Projects funded by CQDM target the development of innovative tools and technologies that accelerate the drug discovery process.
Objectives
CQDM is dedicated first and last to the stimulation of research in the field of therapeutic medicine and in particular to the development of innovative tools facilitating the discovery of safer and more effective compounds. By promoting synergy between academic and industrial research and by creating an international exchange network, CQDM intends to expand Quebec’s leadership in biopharmaceutical research and open new research avenues that will have a strong impact on the industry. CQDM activities also benefit small biotechnology companies. Its unique team approach favours access to internationally renowned experts. By leading research efforts towards market expectations, CQDM fully plays its role in disseminating knowledge and creating economic value.
Québec Consortium for Drug Discovery (CQDM)
7140, Albert-Einstein, suite 100
Montreal (Québec) Canada
H4S 2C1
Tel.: 514 766-6661
Fax: 514 766-9613
email: cqdm@cqdm.org
http://www.cqdm.org/en/index.php
The president & CEO of CQDM discusses her vision of how CQDM’s activities can have a direct impact on the development of safer and more efficient drugs, and how to…
Michel Lavoie, president & CEO of Dermtek Pharma in Canada, discusses the family-owned company’s track record of success over the past three decades, the emphasis they place on R&D and…
Dr. Reza Moridi, Minister of Research, Innovation and Science of the province of Ontario presents the impressive scope of investments undertaken within the fields of innovation and life sciences in…
Greig Estabrooks, general manager of Valneva, talks partnership opportunities for the French-Austrian pure-play vaccine company in Canada, its exciting pipeline, and how he encourages his global R&D colleagues to consider…
Michel Robidoux, president and general manager of Sandoz Canada, charts the extremely successful journey for this Novartis division. He explains the strategy Sandoz Canada has undertaken to expand its portfolio…
Stéphane Lassignardie, General Manager of AbbVie Canada, discusses the significant milestones for AbbVie Canada in the past three years, with major product and indication launches, the various initiatives it has…
Eric Tse, general manager of Shire Canada, highlights the affiliate’s exciting journey over the past four years, including new office location in downtown Toronto, and the launch of six new…
Stefan Larson, CEO of Northern Biologics, explains the major milestones for Northern Biologics over the past three years, his personal motivation for starting a biotech company, their collaboration with Celgene,…
Sylvie Pilon, VP and GM at Lundbeck Canada, shares the highlights of her first year leading the Canadian affiliate; the challenges associated with Canada’s complex market access environment, particularly for…
Vinod Ramachandran, general manager of Dr. Reddy’s Canadian affiliate, highlights the exciting journey of Dr. Reddy’s in Canada since 2013, the company’s upcoming three specialty product launches, and the goal…
Janice Murray, president of Novartis Pharmaceuticals Canada Inc., highlights the track record of excellence Novartis has enjoyed in Canada as the second largest pharma affiliate in the country, the challenge…
Éric Gervais, executive vice-president of Duchesnay Inc, a privately-held, specialty Canadian pharma company focusing on women’s health, charts the company’s successful growth over the past 25 years, the innovative portfolio…
Doug Sommerville, senior vice-president and general manager of Teva Canada, discusses Teva Canada’s enviable top five positioning within the global organization, the strength of Teva’s generics portfolio within Canada, and…
See our Cookie Privacy Policy Here